Structured Review

Illumina Inc truseq amplicon cancer panel tsacp
Truseq Amplicon Cancer Panel Tsacp, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 88/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/truseq amplicon cancer panel tsacp/product/Illumina Inc
Average 88 stars, based on 9 article reviews
Price from $9.99 to $1999.99
truseq amplicon cancer panel tsacp - by Bioz Stars, 2020-07
88/100 stars

Images

Related Articles

Sequencing:

Article Title: Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing
Article Snippet: .. Library preparation and sequencing Initially, libraries of the technical testing cohort were prepared with the TruSeq Amplicon Cancer Panel (TSACP), covering 225 amplicons of 48 cancer associated genes, following exactly the manufacturer’s protocol (Illumina, San Diego, USA). .. Since this did not yield reliable libraries for the different types of FFPE tissue specimens (Additional file : Table S1A), modifications to the library protocol were made to the first hybridization step with oligo pools and to subsequent PCR cycling parameters (see Additional file : Table S1B).

Article Title: Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses
Article Snippet: .. TruSeq Amplicon Cancer Panel Library Preparation and Sequencing The TruSeq Amplicon Cancer Panel (TSACP) (Illumina Inc., San Diego, CA, USA) targets mutational hotspots in 48 cancer-related genes (ABL1 , AKT1 , ALK , APC , ATM , BRAF , CDH1 , CDKN2A , CSF1R , CTNNB1 , EGFR , ERBB2 , ERBB4 , FBXW7 , FGFR1 , FGFR2 , FGFR3 , FLT3 , GNA11 , GNAQ , GNAS , HNF1A , HRAS , IDH1 , JAK2 , JAK3 , KDR , KIT , KRAS , MET , MLH1 , MLP , NOTCH1 , NPM1 , NRAS , PDGFRA , PIK3CA , PTEN , PTPN11 , RB1 , RET , SMAD4 , SMARCB1 , SMO , SRC , STK11 , TP53 and VHL ), selected in accordance with the nature of primary DLBCL CNS, since its behavior resembles a solid tumor. ..

Mutagenesis:

Article Title: Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers *
Article Snippet: .. The KIT mutation status of the cell lines was confirmed using the TruSeq Amplicon - Cancer Panel (TSACP) from Illumina. .. The cells were maintained in Dulbecco's modified Eagle's medium (Gibco Invitrogen) supplemented with 100 units/ml penicillin-streptomycin and 10% exosomes-depleted FBS and maintained at 37 °C with 5% CO2 .

Amplification:

Article Title: Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing
Article Snippet: .. TruSeq amplicon cancer panel The TruSeq Amplicon - Cancer Panel (TSACP) (Illumina, San Diego, CA) comprises 212 amplicons from 48 genes that are simultaneously amplified in a single-tube reaction. ..

Article Title: Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics
Article Snippet: .. TruSeq® amplicon cancer panel (TSACP) The commercially available TSACP (Illumina) is able to detect mutational hotspots of 48 cancer-related genes, consisting of 212 pairs of primers designed to bind at the flanking genomic regions of interest covering 35 kb. .. Two hundred fifty nanograms of input gDNA were used for preparation of PCR-free libraries.

Article Title: Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses
Article Snippet: .. TruSeq Amplicon Cancer Panel Library Preparation and Sequencing The TruSeq Amplicon Cancer Panel (TSACP) (Illumina Inc., San Diego, CA, USA) targets mutational hotspots in 48 cancer-related genes (ABL1 , AKT1 , ALK , APC , ATM , BRAF , CDH1 , CDKN2A , CSF1R , CTNNB1 , EGFR , ERBB2 , ERBB4 , FBXW7 , FGFR1 , FGFR2 , FGFR3 , FLT3 , GNA11 , GNAQ , GNAS , HNF1A , HRAS , IDH1 , JAK2 , JAK3 , KDR , KIT , KRAS , MET , MLH1 , MLP , NOTCH1 , NPM1 , NRAS , PDGFRA , PIK3CA , PTEN , PTPN11 , RB1 , RET , SMAD4 , SMARCB1 , SMO , SRC , STK11 , TP53 and VHL ), selected in accordance with the nature of primary DLBCL CNS, since its behavior resembles a solid tumor. ..

Article Title: Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas
Article Snippet: .. The Illumina TruSeq Amplicon—Cancer Panel (TSACP) was used for amplifying specific genomic regions. .. The NGS panel covering 46 genes were tested on 10 ONB cases while five cases were explored using the extended NGS panel that covers 592 genes (available here: http://www.carismolecularintelligence.com/solid_tumors_international ) [ , ].

Article Title: Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers *
Article Snippet: .. The KIT mutation status of the cell lines was confirmed using the TruSeq Amplicon - Cancer Panel (TSACP) from Illumina. .. The cells were maintained in Dulbecco's modified Eagle's medium (Gibco Invitrogen) supplemented with 100 units/ml penicillin-streptomycin and 10% exosomes-depleted FBS and maintained at 37 °C with 5% CO2 .

Article Title: What Do We Learn from Spheroid Culture Systems? Insights from Tumorspheres Derived from Primary Colon Cancer Tissue
Article Snippet: .. Top mutations were assessed using the TruSeq Amplicon-Cancer panel (TSACP) with the MiSeq platform according to the Illumina guidelines with the following criteria: depth of > 1000 and a variant frequency of > 0.05. .. Differential gene expression and survival analysis Microarrays (ArrayExpress database, accession number E-MTAB-3575) were performed in accordance with standard protocols (see supplementary material and methods section).

Variant Assay:

Article Title: What Do We Learn from Spheroid Culture Systems? Insights from Tumorspheres Derived from Primary Colon Cancer Tissue
Article Snippet: .. Top mutations were assessed using the TruSeq Amplicon-Cancer panel (TSACP) with the MiSeq platform according to the Illumina guidelines with the following criteria: depth of > 1000 and a variant frequency of > 0.05. .. Differential gene expression and survival analysis Microarrays (ArrayExpress database, accession number E-MTAB-3575) were performed in accordance with standard protocols (see supplementary material and methods section).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    Illumina Inc truseq amplicon cancer panel
    Oncoprint visualizing the gene mutation status of APC , KRAS , NRAS , BRAF , PIK3CA , TP53 , FBXW7 and SMAD4 assessed by <t>TruSeq</t> <t>Amplicon</t> Cancer Panel TSACP analysis for stage II ( n = 29) and stage III ( n = 31) colon cancers The rows indicate the gene mutation status of the 60 samples (grey bars) and the black spots depict mutations.
    Truseq Amplicon Cancer Panel, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 91/100, based on 43 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/truseq amplicon cancer panel/product/Illumina Inc
    Average 91 stars, based on 43 article reviews
    Price from $9.99 to $1999.99
    truseq amplicon cancer panel - by Bioz Stars, 2020-07
    91/100 stars
      Buy from Supplier

    86
    Illumina Inc miseq truseq amplicon cancer panel tsacp
    Histogram of mutations detected across samples by Illumina <t>MiSeq</t> <t>TSACP</t> (prospective cohort). In total, 396 mutations were detected in 70 out of 85 (82%) patients that passed DNA-QC parameters. The majority of mutations were previously described in COSMIC (232 out of 396, 59%), while a substantial proportion of mutations was not previously described (95 out of 396, 24%) or only described as a similar mutation in the same amino acid in COSMIC (69 out of 396, 17%). Abbreviations: AA=amino acid; COSMIC=Catalogue of Somatic Mutations in Cancer; DNA-QC=Deoxyribonucleic acid quality control; <t>TSACP=TruSeq</t> <t>Amplicon</t> Cancer Panel.
    Miseq Truseq Amplicon Cancer Panel Tsacp, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/miseq truseq amplicon cancer panel tsacp/product/Illumina Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    miseq truseq amplicon cancer panel tsacp - by Bioz Stars, 2020-07
    86/100 stars
      Buy from Supplier

    Image Search Results


    Oncoprint visualizing the gene mutation status of APC , KRAS , NRAS , BRAF , PIK3CA , TP53 , FBXW7 and SMAD4 assessed by TruSeq Amplicon Cancer Panel TSACP analysis for stage II ( n = 29) and stage III ( n = 31) colon cancers The rows indicate the gene mutation status of the 60 samples (grey bars) and the black spots depict mutations.

    Journal: Oncotarget

    Article Title: Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients

    doi: 10.18632/oncotarget.12510

    Figure Lengend Snippet: Oncoprint visualizing the gene mutation status of APC , KRAS , NRAS , BRAF , PIK3CA , TP53 , FBXW7 and SMAD4 assessed by TruSeq Amplicon Cancer Panel TSACP analysis for stage II ( n = 29) and stage III ( n = 31) colon cancers The rows indicate the gene mutation status of the 60 samples (grey bars) and the black spots depict mutations.

    Article Snippet: Detection of gene mutations Mutation status of APC , TP53 , KRAS , PIK3CA , FBXW7 , SMAD4 , BRAF and NRAS , i.e. genes that are commonly mutated in CRC, was assessed by next generation sequencing analysis of FFPE DNA samples using the TruSeq Amplicon Cancer Panel (TSACP; Illumina Inc, San Diego, CA USA).

    Techniques: Mutagenesis, Amplification

    Mutation frequency by gene from results of ( a ) MALDI-TOF, n = 827, and ( b ) TruSeq Amplicon Cancer Panel, n = 792. Mutation frequency was calculated as number of variant occurrences within each gene divided by the total number of patients

    Journal: Genome Medicine

    Article Title: Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

    doi: 10.1186/s13073-016-0364-2

    Figure Lengend Snippet: Mutation frequency by gene from results of ( a ) MALDI-TOF, n = 827, and ( b ) TruSeq Amplicon Cancer Panel, n = 792. Mutation frequency was calculated as number of variant occurrences within each gene divided by the total number of patients

    Article Snippet: Three molecular profiling assays were used over the study period: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass-spectrometry platform (MassARRAY, Agena Bioscience, San Diego, CA, USA) to genotype 279 mutations within 23 genes (Additional file : Table S1); the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes (Additional file : Table S2); and the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes (Additional file : Table S3).

    Techniques: Mutagenesis, Amplification, Variant Assay

    Distribution of patients by tumor site and most actionable variant identified [ 4 ]. Cases tested with TruSeq Amplicon Cancer Panel (TSACP; n = 792) are shown in ( a ) and ( b ); cases tested by MALDI-TOF MS (n = 827) are shown in ( c ) and ( d ). a Proportion and number of variants by tumor site, TSACP. b Actionability of variants by tumor site, TSACP. c Proportion and number of variants by tumor site, MALDI-TOF. d Actionability of variants per case by tumor site, MALDI-TOF. Patients with more than one variant were counted once by their most actionable variant class. Total number of patients is indicated by value within or below each bar section . “Gyne-other” includes cervical, endometrial, fallopian tube, uterine, and vulvar

    Journal: Genome Medicine

    Article Title: Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

    doi: 10.1186/s13073-016-0364-2

    Figure Lengend Snippet: Distribution of patients by tumor site and most actionable variant identified [ 4 ]. Cases tested with TruSeq Amplicon Cancer Panel (TSACP; n = 792) are shown in ( a ) and ( b ); cases tested by MALDI-TOF MS (n = 827) are shown in ( c ) and ( d ). a Proportion and number of variants by tumor site, TSACP. b Actionability of variants by tumor site, TSACP. c Proportion and number of variants by tumor site, MALDI-TOF. d Actionability of variants per case by tumor site, MALDI-TOF. Patients with more than one variant were counted once by their most actionable variant class. Total number of patients is indicated by value within or below each bar section . “Gyne-other” includes cervical, endometrial, fallopian tube, uterine, and vulvar

    Article Snippet: Three molecular profiling assays were used over the study period: a custom multiplex genotyping panel on a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass-spectrometry platform (MassARRAY, Agena Bioscience, San Diego, CA, USA) to genotype 279 mutations within 23 genes (Additional file : Table S1); the TruSeq Amplicon Cancer Panel (TSACP, Illumina) on the MiSeq sequencer (Illumina) covering regions of 48 genes (Additional file : Table S2); and the Ion AmpliSeq Cancer Panel (ASCP, ThermoFisher Scientific) on the Ion Proton sequencer (ThermoFisher Scientific) covering regions of 50 genes (Additional file : Table S3).

    Techniques: Variant Assay, Amplification, Mass Spectrometry

    Histogram of mutations detected across samples by Illumina MiSeq TSACP (prospective cohort). In total, 396 mutations were detected in 70 out of 85 (82%) patients that passed DNA-QC parameters. The majority of mutations were previously described in COSMIC (232 out of 396, 59%), while a substantial proportion of mutations was not previously described (95 out of 396, 24%) or only described as a similar mutation in the same amino acid in COSMIC (69 out of 396, 17%). Abbreviations: AA=amino acid; COSMIC=Catalogue of Somatic Mutations in Cancer; DNA-QC=Deoxyribonucleic acid quality control; TSACP=TruSeq Amplicon Cancer Panel.

    Journal: British Journal of Cancer

    Article Title: Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail

    doi: 10.1038/bjc.2014.350

    Figure Lengend Snippet: Histogram of mutations detected across samples by Illumina MiSeq TSACP (prospective cohort). In total, 396 mutations were detected in 70 out of 85 (82%) patients that passed DNA-QC parameters. The majority of mutations were previously described in COSMIC (232 out of 396, 59%), while a substantial proportion of mutations was not previously described (95 out of 396, 24%) or only described as a similar mutation in the same amino acid in COSMIC (69 out of 396, 17%). Abbreviations: AA=amino acid; COSMIC=Catalogue of Somatic Mutations in Cancer; DNA-QC=Deoxyribonucleic acid quality control; TSACP=TruSeq Amplicon Cancer Panel.

    Article Snippet: Illumina MiSeq sequencing The Illumina MiSeq TruSeq Amplicon Cancer Panel (TSACP) is a highly multiplexed NGS assay covering 212 ROIs in 48 cancer-related genes , in which 2631 mutations are represented at least twice in the Catalogue of Somatic Mutations in Cancer (COSMIC).

    Techniques: Mutagenesis, Amplification